XELJANZ

August 26, 2019August 26, 2019

Safety Concerns Prompt Prescription Changes Among Gastroenterologists

News

A survey of gastroenterologists in the United States shows that data from the VARSITY clinical trial, as well as safety concerns about the experimental treatment Xeljanz, are affecting how some ... Read more

August 3, 2018August 3, 2018

Pfizer’s Xeljanz Approved in EU for Adults with Moderate to Severe Ulcerative Colitis

News, Ulcerative colitis

The European Commission has approved Pfizer‘s Xeljanz (tofacitinib) for the treatment of adults with moderate to severe active ulcerative colitis (UC) who have failed to fully respond to other therapies. The ... Read more

June 1, 2018June 1, 2018

FDA Approves Pfizer’s Xeljanz, an Oral Twice Daily Treatment for Adults with Moderate to Severe Ulcerative Colitis

News

The U.S. Food and Drug Administration (FDA) has approved the oral therapy Xeljanz (tofacitinib), by Pfizer, to treat adults with moderately to severely active ulcerative colitis (UC), the company announced. The treatment regimen calls ... Read more

March 12, 2018March 12, 2018

FDA Advisory Panel Favors Extended Use of Xeljanz by Certain Ulcerative Colitis Patients

News

An advisory arm of the U.S. Food and Drug Administration (FDA) gave two positive recommendations to Pfizer’s supplemental New Drug Application, seeking FDA approval for extended use of Xeljanz (tofacitinib) by certain adult ... Read more

June 14, 2017

More Bowel Disease Patients Are Switching Therapies Than a Year Ago, Report Says

News

More inflammatory bowel disease patients are switching biologic therapies than in 2016, according to a report by Spherix Global Insights RealWorld Dynamix. The appearance of Janssen’s Stelara (ustekinumab) — approved ... Read more

August 1, 2016August 1, 2016

Promising Phase 3 Trial Results for Ulcerative Colitis Therapy Xeljanz Announced by Pfizer

News

Pfizer has just announced top-line results from OCTAVE Sustain, the third Phase 3 study investigating Xeljanz (tofacitinib citrate) in patients with moderate-to-severe active ulcerative colitis (UC). The OCTAVE Clinical Development ... Read more